Eastern Journal of Psychiatry

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  24 (2024)
Volume  23 (2020)
Volume  22 (2019)
Volume  21 (2018)
Volume  20 (2017)
Volume  19 (2016)
Volume  18 (2015)
Volume  17 (2014)
Volume  16 (2013)
Volume  15 (2012)
Volume  14 (2011)
Volume  13 (2010)
Volume  12 (2009)
Related articles

VOLUME 16 , ISSUE 1-2 ( February-August, 2013 ) > List of Articles

REVIEW ARTICLE

Treatment of Depression in Pregnancy: Current Trend

Satyakam Mohapatra, NM Rath

Citation Information : Mohapatra S, Rath N. Treatment of Depression in Pregnancy: Current Trend. 2013; 16 (1-2):12-16.

DOI: 10.5005/EJP-16-1--2-12

License: CC BY-NC 4.0

Published Online: 13-10-2021

Copyright Statement:  Copyright © 2013; The Author(s).


Abstract

Pregnancy has traditionally been considered a time of emotional well-being for women conferring protection against psychiatric disorders. But depression during pregnancy affects nearly 20% of women. Depression experienced by obstetric patients frequently remains unrecognized and untreated. Lack of adequate management of depression during pregnancy may result in a potentially devastating consequences that impact upon both mother and baby. So clinicians and patients need up-to-date information to assist with decisions about depression treatment during pregnancy

PDF Share
  1. Judd LL, Akiskal HS, Maser JD, et al. Aprospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry 1998; 55: 694-700
  2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 1997; 349: 1498-504
  3. Commonwealth Department of Health and Aged Care, Australian Institute of Health and Welfare. National health priority areas report. Mental Health 1998. Canberra: AIHW; 1999 AIHW Cat. No. PHE13
  4. Liu S, Prince M, Blizard B, et al. The prevalence of psychiatric morbidity and its associated factors in general health care in Taiwan. Psychol Med 2002; 32: 629-37
  5. Statistics Canada. Health indicators, Volume, No. 1, Depression. Ottawa (ON): Statistics Canada, Canadian Institute for Health Information, 2002; Catalogue No: 82-221-XIE
  6. Araya R, Rojas G, Fritsch R, et al. Common mental disorders in Santiago, Chile: prevalence and sociodemographic correlates. Br J Psychiatry 2001; 178: 228-33.
  7. Blehar MC. The NIMH women's mental health program: establishing the public health context for women's mental health. TEN 2001; 3: 42-43 [online]. Available from URL at http://www.nimh.nih.gov/wmhc/bleharten.pdf [Accessed Jan, 2004]
  8. Johanson R, Chapman G, Murray D, et al. The North Staffordshire Maternity Hospital prospective study of pr egnancy-associated depression. J Psychosom Obstet Gynaecol 2000; 21: 93-7
  9. Gaynes BN, et al. Perinatal depression: prevalence, screening accuracy and screening outcomes. Evid Rep/Technol Assess (Summ) 2005:1–8. [PubMed]
  10. McKee MD, Cunningham D, Jankowksi KR, et al. Health-related functional status in pregnancy: relationship to depression and social support in a multi-ethnic population. Obstet Gynecol 2001; 97: 988-93.
  11. Chokka P. Postpartum depression: part 1. Can JCME 2002; 14: 37-48
  12. Pole M, Einarson A, Pairaudeau N, et al. Drug labeling and risk perceptions of teratogenicity: a survey of pregnant Canadian women and their health professionals. J Clin Pharmacol 2000; 40: 573-7.
  13. Marcus SM, Barry KL, Flynn HA, et al. Treatment guidelines for depression in pregnancy. Int J Gynecol Obstet 2001; 72: 61-70
  14. Depression Research at the National Institute of Mental Health. Fact sheet. Bethesda (MD): NIMH, 2001: NIHB publication no. 00-4501. Available at http://www.nimh.nih.gov/publicat/depresfact.cfm Accessed Jan, 2004
  15. Spinelli MG. Antepartum and postpartum depression. J Gend Specif Med 1998; 1: 33-6
  16. Altshuler L, et al. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. [see comments] Am J Psychiatry. 1996;153:592–606.
  17. Yonkers KA, Wisner KL, Stewart DE, Oberlander TF, Dell DL, Stotland N, Ramin S, Chaudron L, Lockwood C. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry. 2009; 31 (5): 403–413. doi: 10.1016/j.genhosppsych.2009.04.003
  18. Wisner K, Perel J, Wheeler S. Tricyclic dose requirements across pregnancy. Am J Psychiatry. 1993;150(10):1541–1542
  19. Chambers CD, Johnson KA, Dick LM, Felix RJ. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996;335:1010–1015
  20. Simon G, Cunningham M, Davis R. Outcomes of prenatal antidepressant exposure. Am J Psychiatry. 2002;159:2055–2061). (Wen S, et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. J Obstet Gynecol. 2006;194:961
  21. Djulus J, et al. Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. J Clin Psychiatry. 2006;67:1280–1284.
  22. Sivojelezova A, Shuhaiber S, Sarkissian L, Einarson A, Koren G. Citalopram use in pregnancy: prospective comparative evaluation ofpregnancy and fetal outcome. J Obs tet Gynecol. 2005;193:2004.
  23. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med. 2004;158:312–316
  24. Costei A, Kozer E, Ho T, Ito S, Koren G. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med. 2002;156:1129–1132.
  25. Sivojelezova A, Shuhaiber S, Sarkissian L, Einarson A, Koren G. Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome. J Obs tet Gynecol. 2005;193:2004).
  26. Simon G, Cunningham M, Davis R. Outcomes of prenatal antidepressant exposure. Am J Psychiatry. 2002;159:2055–2061.
  27. Källén BA, Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol. 2007;79:301–308.
  28. Louik C, Lin A, Werler M, Hernandez-Diaz S, Mitchell A. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med. 2007;356:2675–2683.
  29. Oberlander TF. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using populationbased health data. Birth Defects Res B Dev Reprod Toxicol. 2008;83:68–76.
  30. Chun-Fai-Chan B, et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol. 2005;192:932–936.
  31. Einarson A. Pregnancy outcome following gestational exposure to venlafaxine: A multicenter prospective controlled study. Am J Psychiatry. 2001:158.
  32. Chambers C, et al. Selective serotonin-reuptake inhibitors and risk of persisitent pulmonary hypertension of the newborn. N Engl J Med. 2006;354:579–587.
  33. Källén B, Olausson P. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf. 2008;17:801–806.
  34. Miller L. Use of electroconvulsive therapy during pregnancy. Hosp Commun Psychiatry. 1994;45(5):444–450.
  35. Spinelli M, Endicott J. Controlled clinical trial of interpersonal psychotherapy versus parenting education program for depressed pregnant women. Am J Psychiatry. 2003;160:555–562.
  36. Flynn HA et al. Comparative performance of the Edinburgh Postnatal Depression Scale and the Patient Health Questionnaire-9 in pregnant andnpostpartum women seeking psychiatric services. Psychiatry Res. 2011 May 15;187(1-2):130-4.
  37. National Institute for Health and Clinical Excellence. NICE Clinical Guideline 45 – Antenatal and postnatal mental health: Clinical management and serviceguidance. February 2007. http://www.nice.org.uk/nicemedia/live/11004/30433/30433.pdf Accessed February 21st, 2012
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.